Compare LNN & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNN | SGP |
|---|---|---|
| Founded | 1954 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1995 | 2026 |
| Metric | LNN | SGP |
|---|---|---|
| Price | $106.04 | $35.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $122.00 | $44.00 |
| AVG Volume (30 Days) | ★ 150.6K | 84.2K |
| Earning Date | 10-22-2026 | 11-17-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.33 | N/A |
| Revenue | ★ $635,863,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.22 | N/A |
| P/E Ratio | $20.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $97.27 | $17.06 |
| 52 Week High | $148.00 | $35.75 |
| Indicator | LNN | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 77.19 |
| Support Level | $104.33 | $24.85 |
| Resistance Level | $116.75 | N/A |
| Average True Range (ATR) | 3.66 | 2.05 |
| MACD | 0.27 | 0.67 |
| Stochastic Oscillator | 38.75 | 98.00 |
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.